Preclinical pharmacokinetics, pharmacodynamics and safety of sucroferric oxyhydroxide

Current Drug Metabolism

Volumn 15, Issue 10, 2014, Pages 953-965

  Cozzolino, Mario ^a   Funk, Felix ^b   Rakov, Viatcheslav ^c   Phan, Olivier ^d   Teitelbaum, Isaac ^e  

^a UNIVERSITY OF MILAN   (Italy)

^b Vifor (International) Ltd   (Switzerland)

^c Vifor (International) Inc   (Switzerland)

^d UNIVERSITY OF LAUSANNE   (Switzerland)

^e UNIVERSITY OF COLORADO HOSPITAL   (United States)

Author keywords

Chronic kidney disease (CKD); Dialysis; Hyperphosphataemia; Phosphate; Phosphate binder; Preclinical; Sucroferric oxyhydroxide

Indexed keywords

IRON 59; SUCROFERRIC OXYHYDROXIDE; CHELATING AGENT; DRUG COMBINATION; FERRIC ION; PHOSPHATE; SUCROSE;

ARTICLE; BLOOD VESSEL CALCIFICATION; CHRONIC KIDNEY DISEASE; DOG; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG SAFETY; ERYTHROCYTE; IN VITRO STUDY; IN VIVO STUDY; IRON KINETICS; ISOTOPE LABELING; NONHUMAN; UREMIA; ANIMAL; BLOOD; CHRONIC KIDNEY FAILURE; COMPLICATION; DISEASE MODEL; DRUG COMBINATION; GASTROINTESTINAL ABSORPTION; HUMAN; HYPERPHOSPHATEMIA; KIDNEY; METABOLISM; PATHOPHYSIOLOGY; RAT; RISK ASSESSMENT; VASCULAR CALCIFICATION;

ANIMALS; CHELATING AGENTS; DISEASE MODELS, ANIMAL; DOGS; DRUG COMBINATIONS; FERRIC COMPOUNDS; GASTROINTESTINAL ABSORPTION; HUMANS; HYPERPHOSPHATEMIA; KIDNEY; PHOSPHATES; RATS; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT; SUCROSE; UREMIA; VASCULAR CALCIFICATION;

EID: 84932170258     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/1389200216666150206124424     Document Type: Article

References (71)

1. Jha, V.; Garcia-Garcia, G.; Iseki, K.; Li, Z.; Naicker, S.; Plattner, B.; Saran, R.; Wang, A. Y.; Yang, C. W. Chronic kidney disease: global dimension and perspectives. Lancet, 2013, 382(9888), 260-272.
2. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am. J. Kidney Dis., 2002, 39(2 suppl 1), S1-266.
3. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. Suppl., 2013, 3(4), 1-150.
4. Hutchison, A. J.; Smith, C. P.; Brenchley, P. E. Pharmacology, efficacy and safety of oral phosphate binders. Nat. Rev. Nephrol., 2011, 7(10), 578-589.
5. Levey, A. S.; Coresh, J. Chronic kidney disease. Lancet, 2012, 379(9811), 165-180.
6. Kidney Disease: Improving Global Outcomes (KDIGO) CKD MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int. Suppl., 2009, (113), S1-S130.
7. Moe, S.; Drueke, T.; Cunningham, J.; Goodman, W.; Martin, K.; Olgaard, K.; Ott, S.; Sprague, S.; Lameire, N.; Eknoyan, G. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int., 2006, 69(11), 1945-1953.
8. Hruska, K. A.; Mathew, S.; Lund, R.; Qiu, P.; Pratt, R. Hyperphosphatemia of chronic kidney disease. Kidney Int., 2008, 74(2), 148-157.
9. Tonelli, M.; Pannu, N.; Manns, B. Oral phosphate binders in patients with kidney failure. N. Engl. J. Med., 2010, 362(14), 1312-1324.
10. Cozzolino, M.; Urena-Torres, P.; Vervloet, M. G.; Brandenburg, V.; Bover, J.; Goldsmith, D.; Larsson, T. E.; Massy, Z. A.; Mazzaferro, S. Is chronic kidney disease-mineral bone disorder (CKD-MBD) really a syndrome? Nephrol. Dial. Transplant., 2014, 29(10), 1815-1820.
11. Covic, A.; Kothawala, P.; Bernal, M.; Robbins, S.; Chalian, A.; Goldsmith, D. Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease. Nephrol. Dial. Transplant., 2009, 24(5), 1506-1523.
12. Block, G. A.; Klassen, P. S.; Lazarus, J. M.; Ofsthun, N.; Lowrie, E. G.; Chertow, G. M. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J. Am. Soc. Nephrol., 2004, 15(8), 2208-2218.
13. Kestenbaum, B.; Sampson, J. N.; Rudser, K. D.; Patterson, D. J.; Seliger, S. L.; Young, B.; Sherrard, D. J.; Andress, D. L. Serum phosphate levels and mortality risk among people with chronic kidney disease. J. Am. Soc. Nephrol., 2005, 16(2), 520-528.
14. Palmer, S. C.; Hayen, A.; Macaskill, P.; Pellegrini, F.; Craig, J. C.; Elder, G. J.; Strippoli, G. F. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. J. A. M. A., 2011, 305(11), 1119-1127.
15. Slinin, Y.; Foley, R. N.; Collins, A. J. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. J. Am. Soc. Nephrol., 2005, 16(6), 1788-1793.
16. Block, G. A. Control of serum phosphorus: implications for coronary artery calcification and calcific uremic arteriolopathy (calciphylaxis). Curr. Opin. Nephrol. Hypertens., 2001, 10(6), 741-747.
17. Jono, S.; McKee, M. D.; Murry, C. E.; Shioi, A.; Nishizawa, Y.; Mori, K.; Morii, H.; Giachelli, C. M. Phosphate regulation of vascular smooth muscle cell calcification. Circ. Res., 2000, 87(7), E10-E17.
18. Ciceri, P.; Volpi, E.; Brenna, I.; Arnaboldi, L.; Neri, L.; Brancaccio, D.; Cozzolino, M. Combined effects of ascorbic acid and phosphate on rat VSMC osteoblastic differentiation. Nephrol. Dial. Transplant., 2012, 27(1), 122-127.
19. Adeney, K. L.; Siscovick, D. S.; Ix, J. H.; Seliger, S. L.; Shlipak, M. G.; Jenny, N. S.; Kestenbaum, B. R. Association of serum phosphate with vascular and valvular calcification in moderate CKD. J. Am. Soc. Nephrol., 2009, 20(2), 381-387.
20. Isakova, T.; Gutierrez, O. M.; Chang, Y.; Shah, A.; Tamez, H.; Smith, K.; Thadhani, R.; Wolf, M. Phosphorus binders and survival on hemodialysis. J. Am. Soc. Nephrol., 2009, 20(2), 388-396.
21. Martin, K. J.; Gonzalez, E. A. Prevention and control of phosphate retention/hyperphosphatemia in CKD-MBD: what is normal, when to start, and how to treat? Clin. J. Am. Soc. Nephrol., 2011, 6(2), 440-446.
22. Cozzolino, M.; Mazzaferro, S.; Brandenburg, V. The treatment of hyperphosphataemia in CKD: calcium-based or calcium-free phosphate binders? Nephrol. Dial. Transplant., 2011, 26(2), 402-407.
23. Barreto, F. C.; De Oliveira, R. A.; Oliveira, R. B.; Jorgetti, V. Pharmacotherapy of chronic kidney disease and mineral bone disorder. Expert Opin. Pharmacother., 2011, 12(17), 2627-2640.
24. Chiu, Y. W.; Teitelbaum, I.; Misra, M.; De Leon, E. M.; Adzize, T.; Mehrotra, R. Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. Clin. J. Am. Soc. Nephrol., 2009, 4(6), 1089-1096.
25. Covic, A.; Rastogi, A. Hyperphosphatemia in patients with ESRD: assessing the current evidence linking outcomes with treatment adherence. B. M. C. Nephrol., 2013, 14, 153.
26. Gonzalez-Revalderia, J.; Casares, M.; De Paula, M.; Pascual, T.; Giner, V.; Miravalles, E. Biochemical and hematological changes in low-level aluminum intoxication. Clin. Chem. Lab. Med., 2000, 38(3), 221-225.
27. Plagemann, T.; Prenzler, A.; Mittendorf, T. Considerations about the effectiveness and cost effectiveness of therapies in the treatment of hyperphosphataemia. Health Econ. Rev., 2011, 1(1), 1.
28. Hill, K. M.; Martin, B. R.; Wastney, M. E.; McCabe, G. P.; Moe, S. M.; Weaver, C. M.; Peacock, M. Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease. Kidney Int., 2013, 83(5), 959-966.
29. Moe, S. M.; Chertow, G. M. The case against calcium-based phosphate binders. Clin. J. Am. Soc. Nephrol., 2006, 1(4), 697-703.
30. Chertow, G. M.; Raggi, P.; Chasan-Taber, S.; Bommer, J.; Holzer, H.; Burke, S. K. Determinants of progressive vascular calcification in haemodialysis patients. Nephrol. Dial. Transplant., 2004, 19(6), 1489-1496.
31. Joy, M. S.; Kshirsagar, A.; Candiani, C.; Brooks, T.; Hudson, J. Q. Lanthanum carbonate. Ann. Pharmacother., 2006, 40(2), 234-240.
32. Slatopolsky, E.; Liapis, H.; Finch, J. Progressive accumulation of lanthanum in the liver of normal and uremic rats. Kidney Int., 2005, 68(6), 2809-2813.
33. Lacour, B.; Lucas, A.; Auchere, D.; Ruellan, N.; De Serre Patey, N. M.; Drueke, T. B. Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration. Kidney Int., 2005, 67(3), 1062-1069.
34. Hutchison, A. J.; Barnett, M. E.; Krause, R.; Siami, G. A.; Lanthanum Carbonate Study Group. Lanthanum carbonate treatment, for up to 6 years, is not associated with adverse effects on the liver in patients with chronic kidney disease Stage 5 receiving hemodialysis. Clin. Nephrol., 2009, 71(3), 286-295.
35. Geisser, P.; Philipp, E. PA21: a novel phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease. Clin. Nephrol., 2010, 74(1), 4-11.
36. Wuthrich, R. P.; Chonchol, M.; Covic, A.; Gaillard, S.; Chong, E.; Tumlin, J. A. Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients. Clin. J. Am. Soc. Nephrol., 2013, 8(2), 280-289.
37. Wilhelm, M.; Gaillard, S.; Rakov, V.; Funk, F. The iron-based phosphate binder PA21 has potent phosphate binding capacity and minimal iron release across a physiological pH range in vitro. Clin. Nephrol., 2014, 81(4), 251-258.
38. Ganz, T. Systemic iron homeostasis. Physiol. Rev., 2013, 93(4), 1721-1741.
39. Touati, D. Iron and oxidative stress in bacteria. Arch. Biochem. Biophys., 2000, 373(1), 1-6.
40. Keyer, K.; Imlay, J. A. Superoxide accelerates DNA damage by elevating free-iron levels. Proc. Natl. Acad. Sci. U. S. A., 1996, 93(24), 13635-13640.
41. Brissot, P.; Ropert, M.; Le Lan, C.; Loreal, O. Non-transferrin bound iron: a key role in iron overload and iron toxicity. Biochim. Biophys. Acta., 2012, 1820(3), 403-410.
42. Funk, F.; Ryle, P.; Canclini, C.; Neiser, S.; Geisser, P. The new generation of intravenous iron: chemistry, pharmacology, and toxicology of ferric carboxymaltose. Arzneimittelforschung, 2010, 60(6a), 345-353.
43. Chen, J.; Chloupkova, M. Abnormal iron uptake and liver cancer. Cancer Biol. Ther., 2009, 8(18), 1699-1708.
44. Horl, W. H. New insights into intestinal iron absorption. Nephrol. Dial. Transplant., 2008, 23(10), 3063-3064.
45. Miyazaki, E.; Kato, J.; Kobune, M.; Okumura, K.; Sasaki, K.; Shintani, N.; Arosio, P.; Niitsu, Y. Denatured H-ferritin subunit is a major constituent of haemosiderin in the liver of patients with iron overload. Gut, 2002, 50(3), 413-419.
46. Anderson, G. J.; Frazer, D. M. Hepatic iron metabolism. Semin. Liver Dis., 2005, 25(4), 420-432.
47. Theil, E. C. Ferritin: the protein nanocage and iron biomineral in health and in disease. Inorg. Chem., 2013, 52(21), 12223-12233.
48. Kew, M. C. Hepatic iron overload and hepatocellular carcinoma. Liver Cancer, 2014, 3(1), 31-40.
49. Brissot, P.; Zanninelli, G.; Guyader, D.; Zeind, J.; Gollan, J. Biliary excretion of plasma non-transferrin-bound iron in rats: pathogenetic importance in iron-overload disorders. Am. J. Physiol., 1994, 267(1 Pt 1), G135-142.
50. Piga, A.; Longo, F.; Duca, L.; Roggero, S.; Vinciguerra, T.; Calabrese, R.; Hershko, C.; Cappellini, M. D. High nontransferrin bound iron levels and heart disease in thalassemia major. Am. J. Hematol., 2009, 84(1), 29-33.
51. Lanz, M.; Baldischweiler, J.; Kriwet, B.; Schill, J.; Stafford, J.; Imanidis, G. Chewability testing in the development of a chewable tablet for hyperphosphatemia. Drug Dev. Ind. Pharm., 2013, 40(12), 1623-1631.
52. Phan, O.; Maillard, M.; Peregaux, C.; Mordasini, D.; Stehle, J. C.; Funk, F.; Burnier, M. PA21, a new iron-based noncalcium phosphate binder, prevents vascular calcification in chronic renal failure rats. J. Pharmacol. Exp. Ther., 2013, 346(2), 281-289.
53. Semrin, G.; Fishman, D. S.; Bousvaros, A.; Zholudev, A.; Saunders, A. C.; Correia, C. E.; Nemeth, E.; Grand, R. J.; Weinstein, D. A. Impaired intestinal iron absorption in Crohn's disease correlates with disease activity and markers of inflammation. Inflamm. Bowel. Dis., 2006, 12(12), 1101-1106.
54. Nemeth, E.; Valore, E. V.; Territo, M.; Schiller, G.; Lichtenstein, A.; Ganz, T. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood, 2003, 101(7), 2461-2463.
55. Dittrich, E.; Puttinger, H.; Schneider, B.; Horl, W. H.; Haag-Weber, M.; Vychytil, A. Is absorption of high-dose oral iron sufficient in peritoneal dialysis patients? Perit. Dial. Int., 2000, 20(6), 667-673.
56. Gulec, S.; Anderson, G. J.; Collins, J. F. Mechanistic and regulatory aspects of intestinal iron absorption. Am. J. Physiol. Gastrointest. Liver Physiol., 2014, 307(4), G397-G409.
57. Friedman, B. M.; Baynes, R. D.; Bothwell, T. H.; Gordeuk, V. R.; Macfarlane, B. J.; Lamparelli, R. D.; Robinson, E. J.; Sher, R.; Hamberg, S. Dietary iron overload in southern African rural blacks. S. Afr. Med. J., 1990, 78(6), 301-305.
58. Kew, M. C. Prevention of hepatocellular carcinoma. H. P. B. (Oxford), 2005, 7(1), 16-25.
59. Floege, J.; Covic, A. C.; Ketteler, M.; Rastogi, A.; Chong, E. M.; Gaillard, S.; Lisk, L. J.; Sprague, S. M. A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients. Kidney Int., 2014, 86(3), 638-647.
60. Sprague, S. M.; Covic, A.; Floege, J.; Ketteler, M.; Spinowitz, B.; Gaillard, S.; Moneuse, P.; Rastogi, A. Concomitant intravenous iron use drives changes in iron indices in a Phase 3 study of PA21. Poster presented at the NKF congress, 2014.
61. Kapustin, A. N.; Davies, J. D.; Reynolds, J. L.; McNair, R.; Jones, G. T.; Sidibe, A.; Schurgers, L. J.; Skepper, J. N.; Proudfoot, D.; Mayr, M.; Shanahan, C. M. Calcium regulates key components of vascular smooth muscle cell-derived matrix vesicles to enhance mineralization. Circ. Res., 2011, 109(1), e1-12.
62. Spiegel, D. M.; Brady, K. Calcium balance in normal individuals and in patients with chronic kidney disease on low- and highcalcium diets. Kidney Int., 2012, 81(11), 1116-1122.
63. Jean, G.; Bresson, E.; Terrat, J. C.; Vanel, T.; Hurot, J. M.; Lorriaux, C.; Mayor, B.; Chazot, C. Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences. Nephrol. Dial. Transplant., 2009, 24(3), 948-955.
64. Srivaths, P. R.; Goldstein, S. L.; Silverstein, D. M.; Krishnamurthy, R.; Brewer, E. D. Elevated FGF 23 and phosphorus are associated with coronary calcification in hemodialysis patients. Pediatr. Nephrol., 2011, 26(6), 945-951.
65. Yasin, A.; Liu, D.; Chau, L.; Madrenas, J.; Filler, G. Fibroblast growth factor-23 and calcium phosphate product in young chronic kidney disease patients: a cross-sectional study. B. M. C. Nephrol., 2013, 14, 39.
66. Rodriguez-Ortiz, M. E.; Lopez, I.; Munoz-Castaneda, J. R.; Martinez-Moreno, J. M.; Ramirez, A. P.; Pineda, C.; Canalejo, A.; Jaeger, P.; Aguilera-Tejero, E.; Rodriguez, M.; Felsenfeld, A.; Almaden, Y. Calcium deficiency reduces circulating levels of FGF23. J. Am. Soc. Nephrol., 2012, 23(7), 1190-1197.
67. Scialla, J. J.; Lau, W. L.; Reilly, M. P.; Isakova, T.; Yang, H. Y.; Crouthamel, M. H.; Chavkin, N. W.; Rahman, M.; Wahl, P.; Amaral, A. P.; Hamano, T.; Master, S. R.; Nessel, L.; Chai, B.; Xie, D.; Kallem, R. R.; Chen, J.; Lash, J. P.; Kusek, J. W.; Budoff, M. J.; Giachelli, C. M.; Wolf, M.; The Chronic Renal Insufficiency Cohort Study Investigators. Fibroblast growth factor 23 is not associated with and does not induce arterial calcification. Kidney Int., 2013, 83(6), 1159-1168.
68. Jamal, S. A.; Vandermeer, B.; Raggi, P.; Mendelssohn, D. C.; Chatterley, T.; Dorgan, M.; Lok, C. E.; Fitchett, D.; Tsuyuki, R. T. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet, 2013, 382(9900), 1268-1277.
69. Mason, M. A.; Shepler, B. M. Evaluation of morbidity and mortality data related to cardiovascular calcification from calciumcontaining phosphate binder use in patients undergoing hemodialysis. Pharmacotherapy, 2010, 30(7), 741-748.
70. Raggi, P.; Boulay, A.; Chasan-Taber, S.; Amin, N.; Dillon, M.; Burke, S. K.; Chertow, G. M. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J. Am. Coll. Cardiol., 2002, 39(4), 695-701.
71. Almirall, J.; Veciana, L.; Llibre, J. Calcium acetate versus calcium carbonate for the control of serum phosphorus in hemodialysis patients. Am. J. Nephrol., 1994, 14(3), 192-196.